Manufacturers, Medicare Part D, Out-of-Pocket Expenses

Mintz IRA Update — The Consequences and Costs of Redesigning the Part D Program

Mintz - Health Care Viewpoints on 7/16/2024

The passage of the Inflation Reduction Act of 2022 (IRA) marked a significant milestone in Congress’s ongoing efforts to address escalating health care costs. While the IRA aims to rein in government spending on Medicare and...more

Mintz IRA Update — Other Key IRA Programs and Developments: The Medicare Prescription Drug Inflation Rebate Program and Maximum...

Mintz - Health Care Viewpoints on 9/21/2023

Although most of the recent focus around the implementation of the Inflation Reduction Act (“IRA”) by the press and industry stakeholders has been on the Medicare Drug Price Negotiation Program, the IRA has several other...more

2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes

White & Case LLP on 9/15/2022

States remain at the forefront of legislative efforts on a range of issues relating to drug pricing, such as increasing price transparency, capping out-of-pocket costs for insulin, and limiting certain PBM practices. These...more

OIG denies proposed manufacturer-sponsored copay support program for Medicare beneficiaries

Hogan Lovells on 9/30/2020

On September 23, the HHS OIG published Advisory Opinion No. 20-05, advising that OIG found “highly suspect” a manufacturer’s proposal to create a copay subsidy program to help certain financially eligible Medicare...more

HHS Proposes Rule to Eliminate Safe Harbor for PBM Drug Rebates

Sheppard Mullin Richter & Hampton LLP on 2/12/2019

On February 6, 2019, the Office of the Inspector General of the U.S. Department of Health and Human Services (the “OIG”) published in the Federal Register a proposed rule (the “Proposed Rule”) that, if made final in its...more

Manufacturers › Medicare Part D › Out-of-Pocket Expenses

Mintz IRA Update — The Consequences and Costs of Redesigning the Part D Program

Mintz IRA Update — Other Key IRA Programs and Developments: The Medicare Prescription Drug Inflation Rebate Program and Maximum...

2022 Drug Pricing Update: States Continue Legislative Push Even As Congress Passes Long Sought Changes

OIG denies proposed manufacturer-sponsored copay support program for Medicare beneficiaries

HHS Proposes Rule to Eliminate Safe Harbor for PBM Drug Rebates

"My best business intelligence, in one easy email…"